GlassScriptPhysician profile
Pooja Khatiwada
NPI 1518320746
$2,562.10
in general payments reported to CMS, 2019-2025
14 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $351 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,562.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,484.76 | 2025 | Rapiblyk |
| Pfizer INC. | $289.87 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $225.86 | 2024-2025 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.57 | 2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $88.26 | 2024-2025 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $69.76 | 2025 | |
| Csl Behring | $48.11 | 2025 | Kcentra |
| Melinta Therapeutics, LLC | $47.63 | 2024-2025 | Rezzayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.54 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $38.01 | 2024 | Dificid, Zerbaxa |
| Shionogi INC | $37.68 | 2024-2025 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $27.34 | 2025 | Eliquis |
| Aimmune Therapeutics, INC. | $25.66 | 2025 | Vowst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.05 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Khatiwada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.